SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Maria Aguado Jose)
 

Sökning: WFRF:(Maria Aguado Jose) > (2021) > Efficacy of beta-la...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00010082naa a2200925 4500
001oai:DiVA.org:uu-454583
003SwePub
008210930s2021 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4545832 URI
0247 a https://doi.org/10.1111/tid.135202 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Pierrotti, Ligia C.u Univ Sao Paulo, Hosp Clin, Infect Dis Div, Med Sch, Sao Paulo, Brazil.4 aut
2451 0a Efficacy of beta-lactam/beta-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project)
264 c 2021-01-04
264 1b John Wiley & Sons,c 2021
338 a print2 rdacarrier
520 a Background Whether active therapy with beta-lactam/beta-lactamase inhibitors (BLBLI) is as affective as carbapenems for extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) bloodstream infection (BSI) secondary to urinary tract infection (UTI) in kidney transplant recipients (KTRs) remains unclear. Methods We retrospectively evaluated 306 KTR admitted to 30 centers from January 2014 to October 2016. Therapeutic failure (lack of cure or clinical improvement and/or death from any cause) at days 7 and 30 from ESBL-E BSI onset was the primary and secondary study outcomes, respectively. Results Therapeutic failure at days 7 and 30 occurred in 8.2% (25/306) and 13.4% (41/306) of patients. Hospital-acquired BSI (adjusted OR [aOR]: 4.10; 95% confidence interval [CI]: 1.50-11.20) and Pitt score (aOR: 1.47; 95% CI: 1.21-1.77) were independently associated with therapeutic failure at day 7. Age-adjusted Charlson Index (aOR: 1.25; 95% CI: 1.05-1.48), Pitt score (aOR: 1.72; 95% CI: 1.35-2.17), and lymphocyte count <= 500 cells/mu L at presentation (aOR: 3.16; 95% CI: 1.42-7.06) predicted therapeutic failure at day 30. Carbapenem monotherapy (68.6%, primarily meropenem) was the most frequent active therapy, followed by BLBLI monotherapy (10.8%, mostly piperacillin-tazobactam). Propensity score (PS)-adjusted models revealed no significant impact of the choice of active therapy (carbapenem-containing vs any other regimen, BLBLI- vs carbapenem-based monotherapy) within the first 72 hours on any of the study outcomes. Conclusions Our data suggest that active therapy based on BLBLI may be as effective as carbapenem-containing regimens for ESBL-E BSI secondary to UTI in the specific population of KTR. Potential residual confounding and unpowered sample size cannot be excluded (ClinicalTrials.gov identifier: NCT02852902).
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng
653 a bloodstream infection
653 a carbapenem&#8208
653 a sparing regimen
653 a extended&#8208
653 a spectrum &#946
653 a &#8208
653 a lactamase&#8208
653 a producing Enterobacterales
653 a kidney transplantation
653 a outcomes
653 a urinary tract infection
7001 a Perez-Nadales, Elenau ISCIII, Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Infect Dis Grp, Cordoba, Spain.4 aut
7001 a Fernandez-Ruiz, Mariou ISCIII, Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Complutense, 12 Octubre Univ Hosp, Inst Invest Sanitaria Hosp 12 Octubre imas12, Unit Infect Dis, Madrid, Spain.4 aut
7001 a Gutierrez-Gutierrez, Belenu ISCIII, Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Seville, Virgen Macarena Univ Hosp, Inst Biomed Seville, Clin Unit Infect Dis Microbiol & Prevent Med, Seville, Spain.4 aut
7001 a Hock Tan, Banu Singapore Gen Hosp, Dept Infect Dis, Singapore, Singapore.4 aut
7001 a Carratala, Jordiu ISCIII, Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Barcelona, Bellvitge Univ Hosp IDIBELL, Dept Infect Dis, Barcelona, Spain.4 aut
7001 a Oriol, Isabelu ISCIII, Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Barcelona, Bellvitge Univ Hosp IDIBELL, Dept Infect Dis, Barcelona, Spain.4 aut
7001 a Paul, Micalu Infect Dis Inst, Rambam Hlth Care Campus, Haifa, Israel.4 aut
7001 a Cohen-Sinai, Noau Technion Israel Inst Technol, Haifa, Israel.4 aut
7001 a Lopez-Medrano, Franciscou ISCIII, Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Complutense, 12 Octubre Univ Hosp, Inst Invest Sanitaria Hosp 12 Octubre imas12, Unit Infect Dis, Madrid, Spain.4 aut
7001 a San-Juan, Rafaelu ISCIII, Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Complutense, 12 Octubre Univ Hosp, Inst Invest Sanitaria Hosp 12 Octubre imas12, Unit Infect Dis, Madrid, Spain.4 aut
7001 a Montejo, Miguelu Cruces Univ Hosp, Infect Dis Unit, Bilbao, Spain.4 aut
7001 a Freire, Maristela P.u Univ Sao Paulo, Working Comm Hosp Epidemiol & Infect Control, Hosp Clin, Med Sch, Sao Paulo, Brazil.4 aut
7001 a Cordero, Elisau Univ Seville, Clin Unit Infect Dis Microbiol & Prevent Med, Inst Biomed Seville, Univ Hosp Virgen Rocio,CSIC, Seville, Spain.4 aut
7001 a David, Miruna D.u Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England.4 aut
7001 a Merino, Esperanzau Hosp Gen Univ Alicante, Unit Infect Dis, ISABIAL, Alicante, Spain.4 aut
7001 a Mehta Steinke, Seemau Johns Hopkins Univ, Sch Med, Baltimore, MD USA.4 aut
7001 a Grossi, Paolo A.u Univ Insubria, Dept Med & Surg, Varese, Italy.4 aut
7001 a Cano, Angelau ISCIII, Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Seville, Virgen Macarena Univ Hosp, Inst Biomed Seville, Clin Unit Infect Dis Microbiol & Prevent Med, Seville, Spain.4 aut
7001 a Seminari, Elena M.u Fdn IRCCS Policlin San Matteo, Infect Dis Clin, Pavia, Italy.4 aut
7001 a Valerio, Maricelau Hosp Gen Univ Gregorio Maranon, Clin Microbiol & Infect Dis Dept, Madrid, Spain.4 aut
7001 a Gunseren, Filizu Akdeniz Univ, Dept Infect Dis & Clin Microbiol, Fac Med, Antalya, Turkey.4 aut
7001 a Rana, Meenakshiu Icahn Sch Med Mt Sinai, New York, NY 10029 USA.4 aut
7001 a Mularoni, Alessandrau Ist Mediterraneo Trapianti & Terapie Ad Alta Spec, IRCCS ISMETT, Palermo, Italy.4 aut
7001 a Martin-Davila, Pilaru ISCIII, Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Ramon y Cajal Univ Hosp, Infect Dis Dept, Madrid, Spain.4 aut
7001 a van Delden, Christianu Univ Hosp Geneva, Unit Transplant Infect Dis, Geneva, Switzerland.4 aut
7001 a Hamiyet Demirkaya, Melikeu Baskent Univ, Sch Med, Ankara, Turkey.4 aut
7001 a Kocak Tufan, Zelihau Ankara Yildirim Beyazit Univ, Infect Dis & Clin Microbiol Dept, Med Sch, Ankara, Turkey.4 aut
7001 a Loeches, Belenu Hosp Univ La Paz, Infect Dis Unit, IdiPAZ, Madrid, Spain.4 aut
7001 a Iyer, Ranganathan N.u Global Hosp, Clin Microbiol ID & Infect Control, Hyderabad, India.4 aut
7001 a Soldani, Fabiou Azienda Osped Univ Integrata Verona, Dept Med, Div Infect Dis, Verona, Italy.4 aut
7001 a Eriksson, Britt-Marie,c Docent,d 1952-u Uppsala universitet,Infektionssjukdomar4 aut0 (Swepub:uu)breri424
7001 a Pilmis, Benoitu Paris Descartes Univ, Necker Enfants Malades Univ Hosp, Dept Infect Dis & Trop Med, Ctr Infectiol Necker Pasteur,AP HP,Inst Imagine, Paris, France.4 aut
7001 a Rizzi, Marcou ASST Papa Giovanni XXIII, Infect Dis Unit, Bergamo, Italy.4 aut
7001 a Coussement, Julienu Univ Libre Bruxelles, Div Infect Dis, CUB Hop Erasme, Brussels, Belgium.4 aut
7001 a Clemente, Wanessa T.u Univ Fed Minas Gerais UFMG, Hosp Clin UFMG, Liver Transplant Program, Transplant Infect Dis,Fac Med, Belo Horizonte, MG, Brazil.4 aut
7001 a Roilides, Emmanuelu Aristotle Univ Thessaloniki, Hippokrat Hosp, Infect Dis Unit, Sch Hlth Sci, Thessaloniki, Greece.;Aristotle Univ Thessaloniki, Hippokrat Hosp, Dept Pediat 3, Sch Hlth Sci, Thessaloniki, Greece.4 aut
7001 a Pascual, Alvarou ISCIII, Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Seville, Virgen Macarena Univ Hosp, Inst Biomed Seville, Clin Unit Infect Dis Microbiol & Prevent Med, Seville, Spain.4 aut
7001 a Martinez-Martinez, Luisu ISCIII, Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Cordoba, Clin Unit Microbiol, Maimonides Biomed Res Inst Cordoba IMIBIC, Dept Microbiol,Reina Sofia Univ Hosp, Cordoba, Spain.4 aut
7001 a Rodriguez-Bano, Jesusu ISCIII, Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Seville, Virgen Macarena Univ Hosp, Inst Biomed Seville, Clin Unit Infect Dis Microbiol & Prevent Med, Seville, Spain.4 aut
7001 a Torre-Cisneros, Julianu ISCIII, Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Clin Unit Infect Dis, Cordoba, Spain.4 aut
7001 a Maria Aguado, Joseu ISCIII, Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Complutense, 12 Octubre Univ Hosp, Inst Invest Sanitaria Hosp 12 Octubre imas12, Unit Infect Dis, Madrid, Spain.4 aut
7102 a Univ Sao Paulo, Hosp Clin, Infect Dis Div, Med Sch, Sao Paulo, Brazil.b ISCIII, Spanish Network Res Infect Dis REIPI, Madrid, Spain.;Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Infect Dis Grp, Cordoba, Spain.4 org
7730 t Transplant Infectious Diseased : John Wiley & Sonsg 23:3q 23:3x 1398-2273x 1399-3062
8564 u https://repositorio.unican.es/xmlui/bitstream/10902/21966/1/EfficacyLactamLactamase.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-454583
8564 8u https://doi.org/10.1111/tid.13520

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy